AI 聊天
正在加载 MKGAF 的数据(首次访问,需要几秒钟)。

Merck KGaA

MKGAF · OTC Markets OTCPK · USD

157.97 -3.83 (-2.37%)

收盘价: Oct 19, 2026, 4:00 PM EDT

市值
$68.68B
下次财报日期
Nov 12, 2026

Merck KGaA(MKGAF)股价、分析与数据

时间间隔:1D
正在加载K线和信号…

内在价值

估值模型属于 Pro 功能。登录或升级后可查看完整分析。

查看方案 →

分析师预测

股票预测 →

分析师预测不可用

12个月目标价 · n/a 位分析师

分析师一致意见: n/a

您正在查看免费概览

创建免费账户,探索更多关于此标的的研究资料。

财务表现

查看财务 →

加载中...

最新财报

已公布较预期同比变动
营收—n/an/a
每股收益(TTM)—n/an/a

下次财报

盘中。

预估 · 升级 →

查看财报详情 →

指标

买价
156.91
市值
68.7B
净利润(TTM)
2.37B
0.79
6.36
24.84
n/a
市净率(TTM)
2.02
市销率(TTM)
3.25
财报日期
Nov 12, 2026
卖价
167.5
成交量
61
20日均量
768
开盘价
161.80
前收盘价
161.80
日内区间
161.80 - 161.80
52周区间
116.68 - 175.56
分红
$2.58 (1.59%)
除息日
Apr 27, 2026

关于 Merck KGaA

查看公司资料 →
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG. Drug Manufacturers - Specialty & Generic · Healthcare

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

板块 Healthcare
上市日期 Aug 3, 2012
员工人数 62,136
交易所 OTC Markets OTCPK
股票代码 MKGAF